Medicenna Therapeutics announced the appointment of Humphrey Gardner, M.D., as Chief Medical Officer, CMO, to lead the development strategy and execution of Medicenna’s clinical programs. Dr. Gardner’s career in the biopharmaceutical industry spans over two decades. Most recently, Dr. Gardner served as CMO at Harbour BioMed advancing novel antibody and bispecific therapeutics in oncology.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MDNA:
- Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer
- Medicenna Therapeutics presents preclinical MDNA223 BiSKIT data
- Medicenna Announces Results of Annual and Special Meeting of Shareholders
- Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy
- Medicenna Therapeutics appoints Jeff Caravella as CFO